Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABBV-453 + obinutuzumab
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
ABBV-453 + obinutuzumab is an investigational combination therapy currently being studied for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). **ABBV-453** is an orally available, investigational small molecule whose precise mechanism of action has not been publicly detailed, under development by AbbVie. **Obinutuzumab** (marketed as Gazyva) is a glycoengineered, type II anti-CD20 monoclonal antibody that increases immune-mediated cytotoxicity against B-cells, leading to enhanced cancer cell killing. In this clinical protocol, obinutuzumab is administered intravenously as a debulking agent prior to ABBV-453 dose escalation. The combination is under evaluation for efficacy, safety, and pharmacokinetics in adults with relapsed/refractory CLL/SLL[1][3][5][6].
- Brand names
- Gazyva
- Other names
- ABBV-453ABBV453ABBV 453obinutuzumab
02
Targets
BCL-2 (BCL-2 family)CD20 (B-lymphocyte antigen CD20)
Beyond the preview
Go deeper on ABBV-453 + obinutuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABBV-453 + obinutuzumab.